FOLLICULAR LYMPHOMA GRADE 3B
Clinical trials for FOLLICULAR LYMPHOMA GRADE 3B explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR LYMPHOMA GRADE 3B trials appear
Sign up with your email to follow new studies for FOLLICULAR LYMPHOMA GRADE 3B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough lymphomas: experimental drug TLN-121 enters human testing
Disease control Recruiting nowThis early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New injection shows promise for tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and k…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take on late-stage lymphoma in new trial
Disease control Recruiting nowThis Phase 2 trial is testing a single infusion of axicabtagene ciloleucel, a CAR T-cell therapy, in 45 adults whose diffuse large B-cell lymphoma has returned more than a year after previous treatment. The main goal is to see how many patients have no signs of cancer on a PET/CT…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE2 • Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New gene therapy combo tackles aggressive lymphoma in early trial
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3B
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC